Active Solicitation · DEPARTMENT OF HEALTH AND HUMAN SERVICES

    National Cancer Institute (NCI) Small Business Innovation Research (SBIR) Innovative Concept Award Program – Fiscal Year 2027

    Sol. 75N91026R00109PresolicitationSet-aside: Total Small Business Set-Aside (FAR 19.5)Bethesda, MD
    Open · 4d remaining
    DAYS TO CLOSE
    4
    closes Jul 17, 2026
    POSTED
    Jul 8, 2026
    Publication date
    NAICS CODE
    54171
    Primary industry classification
    PSC CODE
    AN12
    Product & service classification

    AI Summary

    The National Cancer Institute is seeking proposals from small businesses for innovative technologies aimed at treating or preventing pediatric and rare cancers. This solicitation emphasizes the development of therapeutic and diagnostic solutions, with a focus on enhancing entrepreneurial skills and commercialization plans. Proposals must demonstrate technical feasibility and align with the SBIR program's requirements.

    Contract details

    Solicitation No.
    75N91026R00109
    Notice Type
    Presolicitation
    Set-Aside
    Total Small Business Set-Aside (FAR 19.5)
    Posted Date
    July 8, 2026
    Response Deadline
    July 17, 2026
    NAICS Code
    54171AI guide
    PSC / Class Code
    AN12
    Contract Code
    7529
    Issuing Office
    NIH NCI
    Primary Contact
    Kathleen Sears
    State
    MD
    ZIP Code
    20892
    AI Product/Service
    both

    Description

    AMENDMENT 0001: The purpose of this amendment is to clarify submission requirements. White Paper submissions are no longer being requested and will not be accepted under any resultant solicitation. All other terms and conditions remain unchanged. Description The National Cancer Institute (NCI) is soliciting proposals from small business concerns to perform key activities to demonstrate technical feasibility and proof-of-concept for the development of highly innovative and potentially transformative technologies in the following areas: Topic 1: Development of therapeutic or preventative technologies for treatment or prevention of Pediatric Cancers and/or Rare Cancers. Topic 2: Development of devices, diagnostic technologies, or digital health tools for treatment, detection, and diagnosis of Pediatric Cancers and/or Rare Cancers. For this solicitation, rare cancers with a 5-year survival rate of less than 50% are encouraged, and rare cancers include all the cancers listed by the NIH Genetics and Rare Diseases Information Center. For the purposes of this solicitation, a rare cancer is defined in accordance with the U.S. Food and Drug Administration (FDA) Orphan Drug Act as a malignancy with a total U.S. prevalence of fewer than 200,000 individuals. Prevalence estimates should be supported by authoritative data sources (e.g., SEER) or where direct estimates are not available, by scientifically justified epidemiologic approximations based on published literature. For more information regarding 5-year cancer survival rates, see the NCI Surveillance, Epidemiology, and End Results Program (SEER) database at: https://seer.cancer.gov/ Preliminary data is not required. However, the proposal must have a sound scientific premise, either based on the offeror's own research or literature evidence. Proposals shall both identify an anticipated product to be developed and clearly lay out the anticipated development path. Proposals must clearly identify the clinical problem and cancer type(s), along with adequate justification. In addition, offerors should propose experiments to obtain initial de-risking and proof-of-concept data. Awards will also include requirements to enhance entrepreneurial skills, to develop or refine a business model, and a commercialization plan. This Concept Award solicitation is intended to serve as a pipeline for the federal Small Business Innovation Research (SBIR) program. This is a total small business set-aside solicitation, and only proposals from eligible small businesses will be considered for award. This size standard is established by law for the SBIR program, regardless of the NAICS Code assigned. To be eligible as a small business, the offeror may have no more than 500 employees, including the employees of its affiliates (see 13 C.F.R. § 121.702). For other requirements, see the SBA's SBIR/STTR Policy Directive: https://www.sbir.gov/sites/default/files/SBA%20SBIR_STTR_POLICY_DIRECTIVE_May2023.pdf The solicitation for the NCI SBIR Innovative Concept Award Program is anticipated to be made available on or around July 17, 2026. This solicitation is expected to have a closing date in late September for receipt of proposals, with an interim deadline in June for submission and consideration of water papers. which will allow time for the NCI to provide feedback on whether the proposed idea falls within the scope of what this solicitation is seeking. Note – SBIR / STTR Grant Opportunities Other SBIR and STTR contract and grant opportunities are also available. Companies are encouraged to visit: https://seed.nih.gov/small-business-funding/find-funding For general information regarding the NCI SBIR Program, please refer to: https://sbir.cancer.gov/ Attachments/Links: No attachments or links have been added to this opportunity.

    Key dates

    1. July 8, 2026Posted Date
    2. July 17, 2026Proposals / Responses Due

    AI search tags

    Frequently asked questions

    National Cancer Institute (NCI) Small Business Innovation Research (SBIR) Innovative Concept Award Program – Fiscal Year 2027 is a federal acquisition solicitation issued by DEPARTMENT OF HEALTH AND HUMAN SERVICES. Review the full description, attachments, and submission requirements on SamSearch before the response deadline.

    SamSearch Platform

    Stop searching. Start winning.

    AI-powered intelligence for the right opportunities, the right leads, and the right time.